Background Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor
blockers (ARBs), β blockers, and mineralocorticoid receptor antagonists (MRAs) are of …

Aims To evaluate how recommendations of European guidelines regarding
pharmacological and non‐pharmacological treatments for heart failure (HF) are adopted in …

Background Heart failure (HF) is a global challenge, with lower-and middle-income
countries (LMICs) carrying a large share of the burden. Treatment for HF with reduced …

Background Recent registries have shown that recommended drugs for the treatment of
chronic heart failure (CHF) are under‐prescribed in daily practice. Aims To determine …

The extent and impact of under-prescribing of evidence-based pharmacological therapies
among heart failure patients with reduced ejection fraction (HFREF) in contemporary …

Aims Use and dosing of guideline‐directed medical therapy (GDMT) in patients with heart
failure (HF) have been shown to be suboptimal. Among new users of GDMT in HF, we …

Aim Persistent symptoms despite guideline‐directed medical therapy (GDMT) and poor
tolerance of GDMT are hallmarks of patients with advanced heart failure (HF) with reduced …

Aims Surveys on heart failure management suggest under-utilization of life-saving evidence-
based treatment. Evidence-based medicine and clinical guidelines are based on the results …

Aims Patients with heart failure (HF) randomized in controlled trials are generally selected
and do not fully represent the 'real world'. The purpose of this study is to better describe the …

Recommendations represent the core messages of guidelines, and are particularly
important when the body of scientific evidence is rapidly growing, as in the case of heart …